Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A major obstacle in diabetes is the metabolic or hyperglycemic memory, which lacks specific therapies. Here we show that glucose-mediated changes in gene expression largely persist in diabetic kidney disease (DKD) despite reversing hyperglycemia. The senescence-associated cyclin-dependent kinase inhibitor p21 (Cdkn1a) was the top hit among genes persistently induced by hyperglycemia and was associated with induction of the p53-p21 pathway. Persistent p21 induction was confirmed in various animal models, human samples and in vitro models. Tubular and urinary p21-levels were associated with DKD severity and remained elevated despite improved blood glucose levels in humans. Mechanistically, sustained tubular p21 expression in DKD is linked to demethylation of its promoter and reduced DNMT1 expression. Two disease resolving agents, protease activated protein C (3K3A-aPC) and parmodulin-2, reversed sustained tubular p21 expression, tubular senescence, and DKD. Thus, p21-dependent tubular senescence is a pathway contributing to the hyperglycemic memory, which can be therapeutically targeted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420151 | PMC |
| http://dx.doi.org/10.1038/s41467-022-32477-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metformin-improved cognitive impairment in patients with schizophrenia is correlated with activation of tricarboxylic acid cycle and restored functional connectivity of hippocampus.
BMC Med
July 2025
Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha , Hunan, 410011, China.
Background: Cognitive impairment is a prominent feature that adversely affects the long-term prognosis of schizophrenia; yet effective clinical strategies for treatment remain limited. Disruptions in the tricarboxylic acid (TCA) cycle and functional brain abnormalities in the hippocampus may underlie cognitive deficits, although the intrinsic connections between these factors have yet to be fully elucidated. Notably, metformin, a biguanide anti-hyperglycemic agent, has been shown to improve several cognitive domains in patients with schizophrenia and may have the potential to regulate the TCA cycle.
View Article and Find Full Text PDFRhamnan Sulfate from the Seaweed May Improve Cognitive Impairment Caused by Hyperglycemia.
Mar Drugs
June 2025
Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Minamitamagakicho 3500-3, Suzuka 513-8670, Mie, Japan.
Rhamnan sulfate (RS), extracted from the seaweed , suppresses vascular endothelial inflammation and arteriosclerosis, decreases blood glucose levels, and improves blood lipid metabolism and the intestinal environment. We examined whether RS improves hyperglycemia-induced cognitive decline in a hyperglycemic mouse model pretreated with nicotinamide and streptozotocin and then orally administered a high-fat diet and maltodextrin (MD) for 4 months. RS was administered in an MD solution at doses of 75, 225, and 750 mg/kg of mouse body weight.
View Article and Find Full Text PDFProtective effects of Lam. extract against learning and memory dysfunction induced by streptozotocin and amyloid β model.
Arch Physiol Biochem
May 2025
Department of Food Science and Nutrition, Tongmyong University, Busan, Republic of Korea.
Alzheimer's disease (AD) is associated with hyperglycaemia and amyloid beta (Aβ) accumulation. In the present study, we investigated whether an aqueous extract of Lam. (CCWE) improved cognitive disorder in a hyperglycaemic and cognitive-impaired mouse model.
View Article and Find Full Text PDFThe partial clinical remission phase of type 1 diabetes: early-onset dyslipidemia, long-term complications, and disease-modifying therapies.
Front Endocrinol (Lausanne)
May 2025
Division of Endocrinology, Department of Pediatrics, Zucker School of Medicine at Hofstra/Northwell, New York, NY, United States.
No therapy confers complete β-cell protection at any of the 3 stages of type 1 diabetes (T1D). Disease-modifying therapies in type 1 diabetes aim to prolong the preclinical (stages I and II) and the post-diagnostic partial clinical remission (PR) phases of T1D to reduce its short- and long-term complications. These therapies are focused on mitigating β-cell apoptosis by reducing autoimmune attacks on surviving β-cells through several pathways; as well as improving β-cell function to enable the production of functional endogenous insulin and C-peptide through the reduction of proinsulin to C-peptide ratios and other measures.
View Article and Find Full Text PDFQuantitative assessment of metabolic memory and its prediction of renal function decline in patients with type 2 diabetes: A retrospective observational study.
Diabetes Metab Syndr
April 2025
Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan. Electronic address:
Aims: This study quantitatively assesses metabolic memory by modeling the relationship between hyperglycemic exposure and renal function decline in patients with type 2 diabetes (T2D).
Methods: This retrospective longitudinal study included 381 Japanese patients with T2D. Hyperglycemic exposure was presented by calculating the area under the curve (AUC) for HbA1c ≥ 6 % (AUC) during the observation period.